With the successful closing of a hefty Series B financing, Orum Therapeutics is on track to become the first company in the world to bring to the clinic a targeted protein degrader combined with antibody drug conjugate (ADC) technology.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?